Literature DB >> 10165

Serum concentrations of methaqualone after repeated oral doses of a combination formulation to human subjects.

C White, E Doyle, L F Chasseaud, T Taylor.   

Abstract

Concentrations of methaqualone have been measured in the serum of five male human subjects receiving five consecutive evening doses of a combination formulation containing methaqualone (250 mg), carbromal (300 mg) and benactyzine (0.33 mg) in each tablet. After administration of the first dose, mean peak serum concentrations of methaqualone (1.2 mug/ml) occurred at 3 h. After obtaining peak levels, mean concentrations of methaqualone declined rapidly during the next 6 h and thereafter more slowly during the next 18 h. After administration of the last (fifth) dose, mean peak serum concentrations of methaqualone (1.9 mug/ml; 1.5 mug/ml above the predose level) occurred at 2 h. After attaining peak levels, mean concentrations of methaqualone declined rapidly during the next 6 h, and thereafter more slowly, with a half-life of approximately 10 h. Mean concentrations of methaqualone in serum samples 24 h after the second, third, fourth or fifth doses were not significantly different (0.3 mug/ml - 0.6 mug/ml) during this period of dosing. This suggests that significant accumulation of methaqualone in the serum did not occur during a period of five consecutive evening doses of the combination formulation.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 10165     DOI: 10.1007/BF00565624

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  20 in total

1.  [HYPNOTIC PROPERTIES OF METHAQUALONE IN HEALTHY VOLUNTEERS].

Authors:  L TETREAULT; B LAFRENIERE; S BLOOMFIELD; J M BORDELEAU
Journal:  Union Med Can       Date:  1965-03

2.  Hypnotic action of methaqualone.

Authors:  P A COLDREY
Journal:  Practitioner       Date:  1963-03

3.  Methaqualone as a hypnotic.

Authors:  T W PARSONS; T J THOMSON
Journal:  Br Med J       Date:  1961-01-21

4.  Metabolism of methaqualone by the epoxide-diol pathway in man and the rat.

Authors:  W G Stillwell; P A Gregory; M G Horning
Journal:  Drug Metab Dispos       Date:  1975 Jul-Aug       Impact factor: 3.922

5.  Methaqualone pharmacokinetics after single- and multiple-dose administration in man.

Authors:  R K Nayak; R D Smyth; J H Chamberlain; A Polk; A F DeLong; T Herczeg; P B Chemburkar; R S Joslin; N H Reavey-Cantwell
Journal:  J Pharmacokinet Biopharm       Date:  1974-04

6.  Plasma concentrations and effects of methaqualone after single and multiple oral doses in man.

Authors:  G Alván; O Ericsson; S Levander; J E Lindgren
Journal:  Eur J Clin Pharmacol       Date:  1974-10-04       Impact factor: 2.953

7.  [Gas chromatographic determination of methaqualone in small amounts of serum after ingestion of therapeutic doses (author's transl)].

Authors:  S Goenechea; S S Brown; M M Ferguson
Journal:  Arch Toxikol       Date:  1973-08-30

8.  Identification of free and conjugated metabolites of methaqualone by gas chromatography-mass spectrometry.

Authors:  R Bonnichsen; Y Mårde; R Ryhage
Journal:  Clin Chem       Date:  1974-02       Impact factor: 8.327

9.  Plasma levels and absorption of methaqualone after oral administration to man.

Authors:  R N Morris; G A Gunderson; S W Babcock; J F Zaroslinski
Journal:  Clin Pharmacol Ther       Date:  1972 Sep-Oct       Impact factor: 6.875

10.  [On the biotransformation of 2-methyl-3-o-toly-4(3H)-quinazolinone (=methaqualone. 1. Analysis and isolation of renal excretory products as well as the identification of some metabolites].

Authors:  F R Preuss; H M Hassler; R Köpf
Journal:  Arzneimittelforschung       Date:  1966-03
View more
  2 in total

Review 1.  Clinical pharmacokinetics of hypnotics.

Authors:  D D Breimer
Journal:  Clin Pharmacokinet       Date:  1977 Mar-Apr       Impact factor: 6.447

2.  Inter- and intra-individual variation in the metabolism of methaqualone in man after a single oral dose.

Authors:  K Wilson; C N Reynolds; D Burnett
Journal:  Eur J Clin Pharmacol       Date:  1978-06-19       Impact factor: 2.953

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.